| Literature DB >> 29617505 |
Henrique Budib Dorsa Pontes1, José Carlos Dorsa Vieira Pontes2, Euler de Azevedo Neto1, Giovanna Serra da Cruz Vendas1, João Victor Cunha Miranda1, Letícia do Espírito Santos Dias1, João Victor Durães Gomes Oliva1, Murilo Henrique Martins de Almeida1, Ian de Oliveira Chaves1, Tricia Luna Sampaio1, Carlos Henrique Marques Dos Santos1, Doroty Mesquita Dourado1.
Abstract
INTRODUCTION: Reperfusion injury leads to systemic morphological and functional pathological alterations. Some techniques are already estabilished to attenuate the damage induced by reperfusion. Ischemic preconditioning is one of the standard procedures. In the last 20 years, several experimental trials demonstrated that the ischemic postconditioning presents similar effectiveness. Recently experimental trials demonstrated that statins could be used as pharmacological preconditioning.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29617505 PMCID: PMC5873777 DOI: 10.21470/1678-9741-2017-0108
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Mechanism of ischemia-reperfusion and oxidative stress.
I/R=ischemia/reperfusion, ADP=adenosine diphosphate; AMP=adenosine monophosphate; ATP=adenosine triphosphate; IL-1=Interleukin-1; IL-6=Interleukin-6; NO=nitric oxide; OONO-=Peroxynitrite; ROS=reactive oxygen species; TNF-α=tumor necrosis factor alpha
Fig. 2Action mechanism of the statins.
Fig. 3Histopathological analysis of lung, kidney, liver and intestine.
Results of statistic analysis of tissue injuries.
| 1 | 4 | 1 | 1 | 1 | 1 |
| 2 | 4 | 1 | 1 | 1 | 1 |
| 3 | 4 | 2 | 2 | 2 | 1 |
| 4 | 4 | 1 | 1 | 2 | 1 |
| 5 | 4 | 3 | 1 | 1 | 1 |
| 6 | 3 | 2 | 2 | 1 | - |
| 7 | 2 | 1 | 1 | 1 | - |
| 8 | 4 | 1 | 1 | 1 | - |
| 9 | 4 | 2 | 1 | 1 | - |
| AVERAGE | 3.6 | 1.6 | 1.2 | 1.2 | 1 |
| 1 | 3 | 2 | 1 | 1 | 0 |
| 2 | 3 | 1 | 1 | 1 | 0 |
| 3 | 3 | 1 | 2 | 2 | 0 |
| 4 | 3 | 2 | 1 | 2 | 0 |
| 5 | 3 | 2 | 1 | 1 | 0 |
| 6 | 3 | 1 | 2 | 1 | - |
| 7 | 3 | 2 | 1 | 1 | - |
| 8 | 3 | 1 | 1 | 1 | - |
| 9 | 3 | 2 | 1 | 1 | - |
| AVERAGE | 3 | 1.5 | 1.2 | 1.2 | 0 |
| 1 | 2 | 0 | 0 | 0 | 0 |
| 2 | 2 | 0 | 0 | 0 | 0 |
| 3 | 2 | 0 | 0 | 0 | 0 |
| 4 | 2 | 2 | 0 | 0 | 0 |
| 5 | 2 | 2 | 0 | 0 | 0 |
| 6 | 2 | 0 | 0 | 0 | - |
| 7 | 2 | 0 | 0 | 0 | - |
| 8 | 2 | 2 | 0 | 0 | - |
| 9 | 2 | 0 | 0 | 0 | - |
| AVERAGE | 2 | 0.66 | 0 | 0 | 0 |
| 1 | 4 | 2 | 1 | 1 | 1 |
| 2 | 4 | 2 | 1 | 1 | 1 |
| 3 | 4 | 2 | 1 | 1 | 1 |
| 4 | 4 | 4 | 2 | 1 | 1 |
| 5 | 4 | 2 | 1 | 1 | 1 |
| 6 | 4 | 2 | 1 | 2 | - |
| 7 | 4 | 4 | 2 | 1 | - |
| 8 | 4 | 2 | 1 | 1 | - |
| 9 | 4 | 2 | 1 | 1 | - |
| AVERAGE | 4 | 2.44 | 1.22 | 1.11 | 1 |
Fig. 4Graphics analyzing the level of injury among tissues in each organ.
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| ADP | = Adenosine diphosphate | HMG-CoA reductase | = 3-hydroxy-3-methylglutaryl-coenzyme A reductase | |
| ALT | = Alanine transaminase | IL-1 | = Interleukin-1 | |
| AST | = Aspartate transaminase | IL-6 | = Interleukin-6 | |
| ATP | = Adenosine triphosphate | mRNA | = Messenger ribonucleic acid | |
| cAMP | = Cyclic adenosine monophosphate | NADPH | = Nicotinamide adenine dinucleotide phosphate | |
| eNOS | = Endothelial nitric oxide synthase | NO | = Nitric oxide | |
| EROs | = Reactive species of oxygen | OONO | = Peroxynitrite | |
| ET-1 | = Endothelin-1 | ROS | = Reactive oxygen species | |
| FPP | = Farnesyl pyrophosphate | TNF-alpha | = Tumor necrosis factor alpha | |
| GGPP | = Geranylgeranyl pyrophosphate | |||
| Authors' roles & responsibilities | |
|---|---|
| HBDP | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; final approval of the version to be published |
| JCDVP | Substantial contributions to the conception or design of the work; or the acquisition, analysis; final approval of the version to be published |
| EAN | Substantial contributions to the conception or design of the work; or the acquisition, analysis; final approval of the version to be published |
| GSCV | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately resolved; final approval of the version to be published |
| JVCM | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately and resolved; final approval of the version to be published |
| LESD | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately and resolved; final approval of the version to be published |
| JVDGO | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately and resolved; final approval of the version to be published |
| MHMA | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately and resolved; final approval of the version to be published |
| IOC | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately and resolved; final approval of the version to be published |
| TLS | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately and resolved; final approval of the version to be published |
| CHMS | Substantial contributions to the conception or design of the work; final approval of the version to be published |
| DMD | Substantial contributions to the conception or design of the work; or the acquisition, analysis; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |